Maze Therapeutics (MAZE) Revenue (2024 - 2026)

Maze Therapeutics' (MAZE) quarterly Revenue came in at $20.0 million in Q1 2026, up 113.11% quarter-over-quarter from -$152.5 million in Q4 2024.

Maze Therapeutics (MAZE) Revenue (2024 - 2026) Analysis & Trends

Maze Therapeutics has disclosed Revenue across 2 years of filings, most recently posting $20.0 million for Q1 2026.

Revenue for Q1 2026 came in at $20.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $20.0 million (changed N/A YoY), and the FY2024 annual result was $15.0 million, changed N/A from the prior year.
Revenue came in at $20.0 million for Q1 2026 at Maze Therapeutics, up from -$152.5 million in the prior quarter.
In the past five years, Revenue ranged from a high of $150.0 million in Q2 2024 to a low of -$152.5 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	5.21 Mn
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	306.30 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.99 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Maze Therapeutics	1.39 Bn	1.39 Bn	18.21 Mn	20.00 Mn

Download Data